|
|
|
|
|
|
|
29.07.25 - 17:48
|
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025.
Dr. Mates said: "Medincell is entering a new era and I'm excited to help shape its future. Its vision and achievements closely align with my passion for advancing medical innovation and delivering meaningful solutions for patients."
Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies.
Dr. Kunsch said: “Throughout my career, I've seen how innovation and collaboration can transform bold ideas into meaningful impact. These values are deeply rooted at Medincell. They've already taken the company far and laid a strong foundation for a new phase o...
|
|
|
|
|
|
|
|
|
|
|
|
|
24.07.25 - 03:54
|
Mountain Valley MD Holdings Announces Changes to Board of Directors (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.
David Batchelor is a seasoned organizational strategist and business transformation expert with more than 25 years of experience advising executive teams and boards on performance improvement, financial discipline, and enterprise value creation. His work spans a wide range of industries—including finance, healthcare, consumer goods, technology, and manufacturing—and includes engagements with global leaders such as Cisco, Coca-Cola, IBM, Merck, Bayer, and Johnson & Johnson. David brings a unique blend of systems thinking, operational insight, and financial acumen to drive results at the intersection of strategy and execution.
With a strong foundation in governance and performance science, David is particularly skilled in helping organizations optimize capital allocation, align leadership s...
|
|
|
|
|
|
|
23.07.25 - 11:24
|
Johnson & Johnson, Pacira partner to expand osteoarthritis treatment options (PBR)
|
|
|
Osteoarthritis is a degenerative condition impacting more than 30 million adults in the US. This collaboration will focus on the promotion of Zilretta (triamcinolone acetonide extended-release injectable suspension),
The post Johnson & Johnson, Pacira partner to expand osteoarthritis treatment options appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
